All patients
Age < 65y (younger) Age > 65y Age > 75y (older) cancer type (metastatic) cancer type (recurrent) ECOG 0 ECOG 1 Gender, female Gender, male P16 negative (HPV) P16 positive (HPV) PDL1 (CPS < 1) PDL1 (CPS >1) PDL1 (TPS <50%) PDL1 (TPS >50%) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic-recurrent HNSCC (mHNSCC), pembrolizumab based treatment vs. cetuximab based chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.83 [0.70; 0.99]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.78 [0.64; 0.96]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.61 [0.45; 0.83]
KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.63; 0.94]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.63 [0.51; 0.77]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.60 [0.44; 0.81]
0.72 [0.64 ; 0.80 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 6 35% 2,631 moderate serious deaths (OS) (extension)detailed results KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.74 [0.61; 0.90]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.58 [0.44; 0.77]
KEYNOTE-048 (PC vs C ; all population), 2019 0.72 [0.60; 0.87]
0.70 [0.62 ; 0.79 ] KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 3 3% 1,326 moderate not evaluable progression or deaths (PFS)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.34 [1.13; 1.59]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 1.16 [0.96; 1.40]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.99 [0.75; 1.30]
KEYNOTE-048 (PC vs C ; all population), 2019 0.92 [0.77; 1.10]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 0.82 [0.67; 1.00]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 0.73 [0.55; 0.97]
0.98 [0.82 ; 1.18 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 6 78% 2,631 moderate not evaluable objective responses (ORR)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.25; 0.53]
KEYNOTE-048 (P vs C ; CPS > 1), 2019 0.44 [0.29; 0.66]
KEYNOTE-048 (P vs C ; CPS > 20), 2019 0.11 [0.06; 0.20]
KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.69; 1.37]
KEYNOTE-048 (PC vs C ; CPS > 1), 2019 1.03 [0.71; 1.49]
KEYNOTE-048 (PC vs C ; CPS > 20), 2019 1.21 [0.72; 2.05]
0.54 [0.29 ; 0.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (P vs C ; CPS > 1), 2019, KEYNOTE-048 (P vs C ; CPS > 20), 2019, KEYNOTE-048 (PC vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; CPS > 1), 2019, KEYNOTE-048 (PC vs C ; CPS > 20), 2019 6 92% 2,640 moderate not evaluable AE (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.22; 0.44]
0.31 [0.22 ; 0.44 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.69; 1.46]
1.00 [0.69 ; 1.46 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.84 [0.48; 1.48]
KEYNOTE-048 (PC vs C ; all population), 2019 1.21 [0.71; 2.07]
1.02 [0.69 ; 1.50 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.36 [0.23; 0.55]
KEYNOTE-048 (PC vs C ; all population), 2019 1.27 [0.89; 1.83]
0.68 [0.20 ; 2.35 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 95% 1,150 moderate not evaluable TRAE (any grade)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.02; 0.09]
KEYNOTE-048 (PC vs C ; all population), 2019 0.71 [0.30; 1.72]
0.18 [0.01 ; 2.64 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 96% 1,150 moderate not evaluable TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.06; 0.13]
KEYNOTE-048 (PC vs C ; all population), 2019 1.12 [0.78; 1.61]
0.32 [0.03 ; 3.76 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 99% 1,150 moderate not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.35 [0.09; 1.34]
KEYNOTE-048 (PC vs C ; all population), 2019 1.45 [0.57; 3.65]
0.78 [0.20 ; 3.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 66% 1,150 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.47 [0.11 ; 19.25 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.01; 0.16]
KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.89; 2.14]
0.25 [0.01 ; 8.25 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 95% 1,150 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.16 [0.02; 1.31]
KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
0.54 [0.08 ; 3.85 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 65% 1,150 moderate not evaluable Blood and lymphatic system disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.02 [0.01; 0.07]
KEYNOTE-048 (PC vs C ; all population), 2019 1.30 [0.92; 1.82]
0.18 [0.00 ; 9.02 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 98% 1,150 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.13; 6.84]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.15; 7.44]
1.00 [0.25 ; 4.01 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
KEYNOTE-048 (PC vs C ; all population), 2019 1.59 [0.64; 3.94]
0.51 [0.04 ; 6.46 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 80% 1,150 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
KEYNOTE-048 (PC vs C ; all population), 2019 0.62 [0.15; 2.62]
0.43 [0.13 ; 1.42 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (P vs C ; all population), 2019 5.79 [0.29; 116.06]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
3.70 [0.39 ; 35.06 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.07; 0.92]
KEYNOTE-048 (PC vs C ; all population), 2019 1.85 [0.87; 3.97]
0.74 [0.11 ; 5.15 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 85% 1,150 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.07 [0.02; 0.23]
0.07 [0.02 ; 0.23 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable General disorders and administration site conditions TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.08; 0.46]
KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [1.15; 3.13]
0.62 [0.06 ; 5.93 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 95% 1,150 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.91 [0.29 ; 28.79 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.47 [0.11 ; 19.25 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.92 [0.06; 57.35]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
2.00 [0.18 ; 22.10 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.04 [0.02 ; 52.60 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.06; 1.57]
KEYNOTE-048 (PC vs C ; all population), 2019 0.34 [0.07; 1.71]
0.33 [0.11 ; 1.02 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.51 [0.21; 1.20]
0.17 [0.01 ; 2.60 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 73% 1,150 moderate not evaluable Metabolism and nutrition disorders TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.26 [0.14; 0.49]
KEYNOTE-048 (PC vs C ; all population), 2019 0.88 [0.55; 1.41]
0.48 [0.15 ; 1.62 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 89% 1,150 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.13 [0.03; 0.58]
KEYNOTE-048 (PC vs C ; all population), 2019 2.03 [1.04; 3.97]
0.56 [0.04 ; 8.18 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 91% 1,150 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.48 [0.02; 14.29]
KEYNOTE-048 (PC vs C ; all population), 2019 0.52 [0.02; 15.54]
0.50 [0.05 ; 5.51 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.97 [0.47; 2.01]
0.22 [0.01 ; 6.71 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 82% 1,150 moderate not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 3.85 [0.17; 85.65]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
2.32 [0.20 ; 26.51 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.11]
KEYNOTE-048 (PC vs C ; all population), 2019 0.85 [0.56; 1.30]
0.09 [0.00 ; 10.60 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 91% 1,150 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.08 [0.07; 62.36]
1.49 [0.11 ; 19.48 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.42 [0.46; 12.55]
KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.52 [0.79 ; 8.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.09 [0.03 ; 0.28 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.29 [0.11; 0.73]
KEYNOTE-048 (PC vs C ; all population), 2019 0.10 [0.02; 0.45]
0.20 [0.08 ; 0.53 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 26% 1,150 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results KEYNOTE-048 (PC vs C ; all population), 2019 0.11 [0.03; 0.35]
0.11 [0.03 ; 0.35 ] KEYNOTE-048 (PC vs C ; all population), 2019 1 0% 563 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
KEYNOTE-048 (PC vs C ; all population), 2019 2.40 [1.11; 5.16]
0.43 [0.01 ; 19.84 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 86% 1,150 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.04 [0.00; 0.27]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.58; 1.89]
0.23 [0.01 ; 5.94 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 90% 1,150 moderate not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.02; 52.60]
1.00 [0.06 ; 15.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.09 [0.01; 1.73]
KEYNOTE-048 (PC vs C ; all population), 2019 1.47 [0.46; 4.68]
0.52 [0.04 ; 7.08 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 66% 1,150 moderate not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.06; 15.37]
KEYNOTE-048 (PC vs C ; all population), 2019 2.09 [0.19; 23.16]
1.49 [0.24 ; 9.20 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.19 [0.02; 1.62]
KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14]
0.31 [0.08 ; 1.14 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Acute kidney injury AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.93 [0.35; 10.60]
KEYNOTE-048 (PC vs C ; all population), 2019 2.63 [0.51; 13.67]
2.26 [0.69 ; 7.40 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.24 [0.13; 0.44]
KEYNOTE-048 (PC vs C ; all population), 2019 1.65 [1.10; 2.49]
0.64 [0.10 ; 4.24 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 96% 1,150 moderate not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.31 [0.08; 1.16]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.41; 2.66]
0.62 [0.19 ; 2.01 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 53% 1,150 moderate not evaluable Blood and lymphatic system disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.10 [0.06; 0.18]
KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [1.00; 1.94]
0.38 [0.03 ; 4.87 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 99% 1,150 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.28 [0.08; 1.03]
KEYNOTE-048 (PC vs C ; all population), 2019 1.37 [0.59; 3.18]
0.67 [0.14 ; 3.15 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 75% 1,150 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.23 [0.05; 1.11]
KEYNOTE-048 (PC vs C ; all population), 2019 1.04 [0.39; 2.81]
0.56 [0.13 ; 2.37 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 60% 1,150 moderate not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83]
KEYNOTE-048 (PC vs C ; all population), 2019 1.39 [0.31; 6.28]
1.82 [0.66 ; 4.99 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.60 [0.26; 1.42]
KEYNOTE-048 (PC vs C ; all population), 2019 1.52 [0.75; 3.08]
0.99 [0.40 ; 2.45 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 63% 1,150 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 1.61 [0.84; 3.11]
0.27 [0.01 ; 13.91 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 87% 1,150 moderate not evaluable Gastrointestinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.33 [0.20; 0.56]
KEYNOTE-048 (PC vs C ; all population), 2019 1.38 [0.92; 2.06]
0.69 [0.17 ; 2.75 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 94% 1,150 moderate not evaluable General disorders and administration site conditions AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.42 [0.23; 0.75]
KEYNOTE-048 (PC vs C ; all population), 2019 1.71 [1.09; 2.67]
0.86 [0.22 ; 3.39 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 93% 1,150 moderate not evaluable Hypertension AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 7.74 [0.41; 147.13]
KEYNOTE-048 (PC vs C ; all population), 2019 17.10 [0.98; 299.27]
11.64 [1.49 ; 90.62 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.96 [0.02; 48.37]
0.96 [0.02 ; 48.37 ] KEYNOTE-048 (P vs C ; all population), 2019 1 0% 587 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.38 [0.07; 1.97]
KEYNOTE-048 (PC vs C ; all population), 2019 0.41 [0.08; 2.14]
0.39 [0.12 ; 1.27 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Leucopenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.57 [0.25; 1.31]
0.17 [0.01 ; 3.10 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 75% 1,150 moderate not evaluable Metabolism and nutrition disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.51 [0.33; 0.77]
KEYNOTE-048 (PC vs C ; all population), 2019 1.11 [0.76; 1.63]
0.76 [0.35 ; 1.63 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 86% 1,150 moderate not evaluable Mucosal inflammation AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.25 [0.08; 0.75]
KEYNOTE-048 (PC vs C ; all population), 2019 1.97 [1.02; 3.78]
0.73 [0.10 ; 5.61 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 90% 1,150 moderate not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.44]
KEYNOTE-048 (PC vs C ; all population), 2019 0.98 [0.48; 1.98]
0.21 [0.01 ; 6.94 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 83% 1,150 moderate not evaluable Nervous system disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.40 [0.18; 0.85]
KEYNOTE-048 (PC vs C ; all population), 2019 0.90 [0.48; 1.67]
0.61 [0.28 ; 1.37 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 62% 1,150 moderate not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.01 [0.00; 0.09]
KEYNOTE-048 (PC vs C ; all population), 2019 0.80 [0.53; 1.22]
0.11 [0.00 ; 6.60 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 94% 1,150 moderate not evaluable Pneumonitis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.80 [0.41; 1.56]
KEYNOTE-048 (PC vs C ; all population), 2019 0.77 [0.38; 1.53]
0.78 [0.49 ; 1.27 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.11 [0.02; 0.47]
KEYNOTE-048 (PC vs C ; all population), 2019 0.06 [0.01; 0.44]
0.09 [0.03 ; 0.28 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Renal and urinary disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.15 [0.35; 3.81]
KEYNOTE-048 (PC vs C ; all population), 2019 1.90 [0.63; 5.75]
1.51 [0.67 ; 3.40 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Respiratory, thoracic and mediastinal disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.17 [1.12; 4.18]
KEYNOTE-048 (PC vs C ; all population), 2019 2.56 [1.33; 4.91]
2.36 [1.48 ; 3.74 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Sepsis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.91 [0.58; 14.53]
KEYNOTE-048 (PC vs C ; all population), 2019 2.10 [0.38; 11.53]
2.49 [0.77 ; 8.03 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Skin and subcutaneous tissue disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 1.61 [0.58; 4.50]
KEYNOTE-048 (PC vs C ; all population), 2019 1.22 [0.40; 3.67]
1.42 [0.67 ; 3.00 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable Stomatitis AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.05 [0.00; 0.80]
KEYNOTE-048 (PC vs C ; all population), 2019 2.52 [1.18; 5.39]
0.44 [0.01 ; 21.27 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 86% 1,150 moderate not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.03 [0.00; 0.25]
KEYNOTE-048 (PC vs C ; all population), 2019 1.00 [0.56; 1.78]
0.21 [0.01 ; 5.80 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 90% 1,150 moderate not evaluable Vascular disorders AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.76 [0.35; 1.64]
KEYNOTE-048 (PC vs C ; all population), 2019 1.57 [0.80; 3.09]
1.12 [0.55 ; 2.29 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 48% 1,150 moderate not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 0.12 [0.01; 0.94]
KEYNOTE-048 (PC vs C ; all population), 2019 1.31 [0.51; 3.37]
0.47 [0.05 ; 4.90 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 77% 1,150 moderate not evaluable Weight decreased AE (grade 3-4)detailed results KEYNOTE-048 (P vs C ; all population), 2019 2.26 [0.58; 8.83]
KEYNOTE-048 (PC vs C ; all population), 2019 2.83 [0.74; 10.76]
2.53 [0.98 ; 6.58 ] KEYNOTE-048 (P vs C ; all population), 2019, KEYNOTE-048 (PC vs C ; all population), 2019 2 0% 1,150 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 05:40 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 276,103,277,102,109,278,101,192,114
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561